The evolving molecular epidemiology of HIV-1 envelope subtypes in injecting drug users in Bangkok, Thailand: implications for HIV vaccine trials.

Important note: Information in this article was accurate in 1996. The state of the art may have changed since the publication date.

The evolving molecular epidemiology of HIV-1 envelope subtypes in injecting drug users in Bangkok, Thailand: implications for HIV vaccine trials.

AIDS. 1995 Aug;9(8):851-7. Unique Identifier : AIDSLINE MED/96014957
Kalish ML; Baldwin A; Raktham S; Wasi C; Luo CC; Schochetman G; Mastro TD; Young N; Vanichseni S; Rubsamen-Waigmann H; et al; Division of HIV/AIDS, Centers for Disease Control and Prevention,; Atlanta, Georgia 30333, USA.

Abstract: OBJECTIVE: To genetically characterize HIV-1 strains in injecting drug users (IDU) in Bangkok, Thailand in 1994, and compare these with strains found earlier in Thai IDU; such information is essential for HIV-1 vaccine development and evaluation. METHODS: Peripheral blood mononuclear cells were collected from 84 IDU attending 14 drug treatment clinics in Bangkok in 1994. DNA was amplified using a nested polymerase chain reaction (PCR) procedure and sequenced directly (without cloning) from the PCR products. The V3 and flanking regions (345 nucleotides) of the env gene were analyzed using a neighbor-joining tree. RESULTS: Only one (1%) strain was a typical subtype B virus, 69 (82%) were genetically distinct subtype B' viruses (Thai B), and 14 (17%) were subtype E strains (Thai A). Persons with recently acquired infection were more likely to have subtype E viruses (P < 0.001) than those in our 1991 survey, who were more likely to have subtype B' viruses. Pairwise intra-subtype differences within subtypes E and B' were 5.3 and 4.3%, respectively, compared with 3.4 and 3.5% among strains collected in 1991 in Thailand. CONCLUSION: The genetic diversity within subtypes B' and E in Thailand and the proportion of new infections due to subtype E viruses among Bangkok IDU are increasing significantly. These data highlight the importance of monitoring the molecular epidemiology of HIV-1 in populations being considered for HIV-1 vaccine trials.

Keywords: Amino Acid Sequence AIDS Vaccines/PHARMACOLOGY Base Sequence Clinical Trials DNA Primers/GENETICS DNA, Viral/GENETICS Epidemiology, Molecular Female *Genes, env Glycosylation Human HIV Envelope Protein gp120/CHEMISTRY/GENETICS HIV Infections/*COMPLICATIONS/EPIDEMIOLOGY/*VIROLOGY HIV-1/*CLASSIFICATION/*GENETICS/ISOLATION & PURIF Male Molecular Sequence Data Phylogeny Sequence Homology, Amino Acid Substance Abuse, Intravenous/*COMPLICATIONS/*VIROLOGY Thailand/EPIDEMIOLOGY Variation (Genetics) JOURNAL ARTICLE
960228
M9621072

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1996. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1996. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .